Review Report on CCL5 Target / Biomarker Content of Review Report on CCL5 Target / Biomarker
CCL5
Other Name(s): C-C motif chemokine ligand 5, transcript variant 2 | C-C motif chemokine 5 isoform 2 precursor (isoform 2) | CCL5_HUMAN | Small inducible cytokine subfamily A (Cys-Cys), member 5 | SISd | Beta-chemokine RANTES | EoCP | RANTES(3-68) | RANTES(4-68) | T-cell-specific protein RANTES | Small inducible cytokine chemokine A5 | regulated upon activation, normally T-expressed, and presumably secreted | Eosinophil chemotactic cytokine | small inducible cytokine subfamily A (Cys-Cys), member 5 | D17S136E | eoCP | SIS-delta | C-C motif chemokine 5 (isoform 1) | chemokine (C-C motif) ligand 5 | C-C motif chemokine ligand 5, transcript variant 1 | Regulated upon activation, normally T-expressed, and presumably secreted | T-cell specific RANTES protein | T cell-specific protein P228 | C-C motif chemokine ligand 5 | CC chemokine ligand 5 | CCL5 variant 1 | SCYA5 | TCP228 | beta-chemokine RANTES | Small-inducible cytokine A5 | eosinophil chemotactic cytokine | CCL5 variant 2 | T-cell specific protein p288 | C-C motif chemokine 5 | RANTES

Drug Target and Biomarker: CCL5

CCL5 plays a role in recruiting mesenchymal stem cells (MSCs) to the site of breast tumors, promoting their secretion of CXCL10 and CCL5, which enhance the metastatic potential of breast cancer cells (BCCs). Additionally, CCL5 stimulates BCCs and stromal cells to secrete matrix metalloproteinases (MMPs), facilitating the breakdown of the extracellular matrix and further promoting BCC metastasis.

In the context of glioblastoma (GBM), CCL5-CCR5 signaling contributes to cancer progression and the homing of cancer stem cells to their niche. Both GBM cells and stromal cells express CCL5 and its receptor CCR5, leading to mutual activation and stimulation in a paracrine signaling manner. This interaction influences local immunity modulation and attracts effector cells.

The release of CCL5, along with other cyto/chemokines, is associated with inflammatory and tolerogenic activities at the maternal-fetal interface during placental development. However, AMA peptides negatively impact this process, affecting cellular homeostasis and causing dysregulation of cellular outcomes.

Radiation exposure leads to the activation of various molecular effects involving CCL5, such as the upregulation of CCL5 and CCL2 to attract T cell infiltration in the tumor microenvironment. Additionally, radiation-generated dsDNA fragments activate the STING pathway to induce T cell activation.

In the context of rheumatoid arthritis (RA), BMP (Bone Morphogenetic Protein) signaling and CCL5 are involved in the pathogenesis of the disease. BMP production appears to have an anti-inflammatory role under normal conditions, downregulating pro-inflammatory cytokines and chemokines. However, in the presence of increased levels of pro-inflammatory factors like TNF-alpha and IL-17, synoviocytes become activated and produce higher levels of BMPs. This, in turn, contributes to the recruitment and activation of immune cells, along with increased levels of pro-inflammatory factors, contributing to RA.

Overall, CCL5 is involved in various biological processes related to cancer progression, immune modulation, placental development, radiation-induced effects, and rheumatoid arthritis pathogenesis.

Protein Name: C-C Motif Chemokine Ligand 5

Functions: Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) (PubMed:16791620, PubMed:1380064, PubMed:8525373, PubMed:9516414, PubMed:15923218). May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells (PubMed:23979485)

The "CCL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C